Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes
- 1 September 2008
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 295 (3), G570-G580
- https://doi.org/10.1152/ajpgi.00542.2007
Abstract
We previously reported that both the concentrative (hCNT) and equilibrative (hENT) nucleoside transporters are expressed in the human liver ( 21 ). Here we report a study that investigated the expression of these transporters (transcripts and proteins) and their role in the hepatobiliary transport of nucleosides/nucleoside drugs using sandwich-cultured human hepatocytes. In the hepatic tissue, the rank order of the mRNA expression of the transporters was hCNT1 ≈ hENT1 > hENT2 ≈ hCNT2 > hCNT3. In sandwich-cultured hepatocytes, the mRNA expression of hCNT2 and hENT2 was comparable to that in hepatic tissue, whereas the expression of corresponding transporters in the two-dimensional hepatocyte cultures was lower. Colocalization studies demonstrated predominant localization of these transporters at the sinusoidal membrane and of hENT1, hCNT1, and hCNT2 at the canalicular membrane. In the sandwich-cultured hepatocytes, ENTs were the major contributors to the transport of thymidine (hENT1, 63%; hENT2, 23%) or guanosine (hENT1, 53%; hENT2, 24%) into the hepatocytes followed by hCNT1 (10%) for thymidine or hCNT2 (23%) for guanosine. Although ribavirin was predominately transported (89%) into the hepatocytes by hENT1, fialuridine (FIAU) was transported by both hENT1 (30%) and hCNTs (61%). The extensively metabolized natural nucleosides were not effluxed into the bile, whereas significant biliary-efflux was observed of FIAU (19%), ribavirin (30%), and formycin B (35%). We conclude that the hepatic activity of hENT1 and hCNT1/2 transporters will determine the in vivo hepatic distribution and therefore the efficacy and/or toxicity of nucleoside drugs used to treat hepatic diseases.Keywords
This publication has 41 references indexed in Scilit:
- In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placentaAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2007
- Transcription factors involved in the expression of SLC28 genes in human liver parenchymal cellsBiochemical and Biophysical Research Communications, 2007
- Peginterferon and Ribavirin for Chronic Hepatitis CNew England Journal of Medicine, 2006
- Electrophysiological Characterization and Modeling of the Structure Activity Relationship of the Human Concentrative Nucleoside Transporter 3 (hCNT3)Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2006
- Role of Glycosylation in Trafficking of Mrp2 in Sandwich-Cultured Rat HepatocytesMolecular Pharmacology, 2005
- Long Term Endocrine Regulation of Nucleoside Transporters in Rat Intestinal Epithelial CellsThe Journal of general physiology, 2004
- Mitochondrial Expression of the Human Equilibrative Nucleoside Transporter 1 (hENT1) Results in Enhanced Mitochondrial Toxicity of Antiviral DrugsPublished by Elsevier BV ,2004
- Simultaneous Expression of hCNT1-CFP and hENT1-YFP in Madin-Darby Canine Kidney CellsJournal of Biological Chemistry, 2002
- Differential expression and regulation of nucleoside transport systems in rat liver parenchymal and hepatoma cellsHepatology, 1998
- Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine‐sensitive (es)‐nucleoside transportersBritish Journal of Pharmacology, 1998